Page 97 - Read Online

Page 26 of 26 Skorupan et al. J Cancer Metastasis Treat 2023;9:5 https://dx.doi.org/10.20517/2394-4722.2022.106

PMC
174. Cananzi FC, Jayanth A, Lorenzi B, et al. “Chronic” metastatic pancreatic acinar cell carcinoma. Pancreatology 2013;13:549-52. DOI
PubMed
175. Jauch SF, Morris VK, Jensen CT, Kaseb AO. Multimodal approach and long-term survival in a patient with recurrent metastatic
acinar cell carcinoma of the pancreas: a case report. Pancreatology 2016;16:153-6. DOI PubMed
176. Jimbo M, Batista PM, Baliff JP, Yeo CJ. Neoadjuvant chemotherapy and appleby procedure for pancreatic acinar cell carcinoma: a
case report. Case Rep Pancreat Cancer 2016;2:46-9. DOI PubMed PMC
177. Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell
carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas 2021;50:77-82. DOI PubMed PMC
178. Xu JY, Guan WL, Lu SX, et al. Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of
literature. Clin Med Insights Oncol 2022;16:11795549221090186. DOI PubMed PMC
179. Lowery MA, Klimstra DS, Shia J, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare
malignancy. Oncologist 2011;16:1714-20. DOI PubMed PMC
180. Schempf U, Sipos B, König C, Malek NP, Bitzer M, Plentz RR. FOLFIRINOX as first-line treatment for unresectable acinar cell
carcinoma of the pancreas: a case report. Z Gastroenterol 2014;52:200-3. DOI PubMed
181. Hashimoto M, Hikichi T, Suzuki T, et al. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell
carcinoma. Clin J Gastroenterol 2017;10:564-9. DOI PubMed
182. Busch E, Kreutzfeldt S, Agaimy A, et al. Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic
acinar cell carcinoma. Cold Spring Harb Mol Case Stud 2020;6:a005553. DOI PubMed PMC
183. Cramer S, Marcus MA, Ramkissoon S, Szabo S, Pressey JG. Pediatric BRAF (V600E)-mutated pancreatic acinar cell carcinoma with
complete and durable response to dabrafenib and trametinib. JCO Precis Oncol 2020;4:801-5. DOI PubMed
184. Gaule M, Pesoni C, Quinzii A, et al. Exceptional clinical response to alectinib in pancreatic acinar cell carcinoma with a novel ALK-
KANK4 gene fusion. JCO Precis Oncol 2022;6:e2100400. DOI PubMed PMC
185. Maehira H, Iida H, Mori H, et al. Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who
received a chemotherapy regimen containing cisplatin and irinotecan. Clin J Gastroenterol 2021;14:1772-8. DOI PubMed
186. Qin L, Shen J, Yang Y, Zou Z. Rapid response to the combination of lenvatinib and sintilimab in a pancreatic acinar cell carcinoma
patient with elevated alpha-fetoprotein: a case report. Front Oncol 2021;11:692480. DOI PubMed PMC
187. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med
2020;382:1894-905. PubMed
188. Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim
analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20:711-8. DOI PubMed
189. Tiriac H, Belleau P, Engle DD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer
Discov 2018;8:1112-29. DOI PubMed PMC
190. O’Kane GM, Grünwald BT, Jang GH, et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic
cancer. Clin Cancer Res 2020;26:4901-10. DOI